Amyloidogenic processing of amyloid β protein precursor (APP) is enhanced in the brains of alcadein α-deficient mice

Alzheimer’s disease (AD) is a very common neurodegenerative disorder, chiefly caused by increased production of neurotoxic β-amyloid (Aβ) peptide generated from proteolytic cleavage of β-amyloid protein precursor (APP). Except for familial AD arising from mutations in the APP and presenilin (PSEN) genes, the molecular mechanisms regulating the amyloidogenic processing of APP are largely unclear. Alcadein α/calsyntenin1 (ALCa/CLSTN1) is a neuronal type I transmembrane protein that forms a complex with APP, mediated by the neuronal adaptor protein X11-like (X11L or MINT2). Formation of the ALCa–X11L–APP tripartite complex suppresses Aβ generation in vitro, and X11L-deficient mice exhibit enhanced amyloidogenic processing of endogenous APP. However, the role of ALCa in APP metabolism in vivo remains unclear. Here, by generating ALCa-deficient mice and using immunohistochemistry, immunoblotting, and co-immunoprecipitation analyses, we verified the role of ALCa in the suppression of amyloidogenic processing of endogenous APP in vivo. We observed that ALCa deficiency attenuates the association of X11L with APP, significantly enhances amyloidogenic β-site cleavage of APP, especially in endosomes, and increases the generation of endogenous Aβ in the brain. Furthermore, we noted amyloid plaque formation in the brains of human APP-transgenic mice in an ALCa-deficient background. These results unveil a potential role of ALCa in protecting cerebral neurons from Aβ-dependent pathogenicity in AD.

Alzheimer’s disease (AD) is the most common neurodegenerative disorder, primarily caused by augmented production of neurotoxic β-amyloid (Aβ) peptide generated from one of the alternative proteolytic cleavages of β-amyloid protein precursor (APP). One of the factors that could affect the onset of AD is the alteration of Aβ generation in quality and quantity.

In familial AD cases associated with causative mutations in PSEN genes, neurotoxic longer Aβ species such as Aβ42 increase along with attenuated γ-secretase activity (1). Similar altered γ-secretase activity is also observed in brains of sporadic AD subjects (2). In another familial AD case associated with causative mutations in the APP gene, Aβ generation altered in quality and quantity is induced (3–6). Mutations in Aβ sequence also alter the aggregative state of Aβ (7). Individuals with Down syndrome carry an extra copy of chromosome 21, where the APP gene resides, and are prone to develop AD in their 50s or 60s (reviewed in Ref. 8), suggesting that even a relatively moderate increase in Aβ generation may affect the onset of AD. Although the primary causes of sporadic AD may be various and it is still controversial whether altered Aβ generation in quality and quantity contributes to the pathology of sporadic AD (9–11), there are reports that Aβ generation can be altered qualitatively and/or quantitatively in the absence of pathogenic mutations on causative genes (12, 13). These observations underscore the relevance of elucidating modulatory factors involved in amyloidogenic processing of endogenous APP in vivo.

One such factor is a submembrane scaffolding protein, X11-like (X11L), encoded by the APBA2 gene. X11L was isolated as a binding partner of APP and shown to suppress Aβ generation in vitro (14). Although overexpressed X11L suppressed overall metabolism of APP in vitro (14, 15), loss of X11L protein preferentially enhanced the amyloidogenic cleavage of APP in the brains of X11L-deficient mice (16, 17). Furthermore, amyloid plaque formation in the brains of human APP-transgenic mice was facilitated in an X11L-deficient background (18). Aβ generation in the brain was suppressed in transgenic mice producing increased amounts of X11L (19). These results indicate that X11L is involved in the suppression of amyloidogenic processing of APP; however, it is unclear whether other molecules associated with X11L affect APP metabolism.

Alcadein α (ALCa) was isolated as a single-pass transmembrane protein, and it binds to X11L through its cytoplasmic region (20). AlCa colocalizes with APP in dystrophic neurites and senile plaques of AD patients’ postmortem brains, suggesting that the AlCa may be involved in AD pathogenesis (20). This notion is further supported by reduced expression of AlCa in AD patients’ brains (21). AlCa is one of three closely related protein family members (AlCa, AlCB, and AlCy). It was also identified as a postsynaptic Ca2+-binding protein calcytenin1 (Clstn1) (20, 22). Binding of APP to X11L in vitro is strengthened in the presence of AlCa by the formation of a tripartite complex comprising APP, X11L, and AlCa (20, 23). APP within the tripartite complex is subject to greater suppression of
proteolytic processing compared with APP with X11L alone in transient expression studies (20, 23). These results suggest that Alcα may play a role in APP metabolism. In addition, Alcs are subject to proteolytic processing as is APP, the quality and quantity of which may correlate with a pathogenic processing of APP (24, 25).

APP generates a p3 fragment by sequential cleavages with α-secretase (mainly ADAM10/17) and γ-secretases. We have shown that Alcα is also cleaved by these proteases to generate a p3-Alcα fragment (26). APP is alternatively cleaved by a combination of β-secretase (BACE1) and γ-secretases to generate Aβ peptide (reviewed in Ref. 27). Alcs are not cleaved by BACE1; however, the generation of p3-Alcα from Alcα likely correlates with pathobiology in Alzheimer’s disease. We have shown that the quantity and quality of p3-Alcα peptide in cerebrospinal fluid and blood are altered and correlate with AD pathogenesis (28–32). Another in vitro study showed that siRNA-mediated reduction of Alcα, in cultured neurons, enhanced amyloidogenic processing of APP (21). These observations collectively suggest a functional link between Alcα and APP metabolism; however, the physiological significance of Alcα in APP metabolism in vivo remains unclear.

Here, we explored the role of Alcα in APP metabolism, in vivo, by generating Alcα-deficient mice. The β-site cleavage of endogenous APP and generation of Aβ were enhanced in the brains of Alcα-deficient mice, and amyloid plaque formation was facilitated in the brains of human APP-producing transgenic mice in an Alcα-deficient background. These observations indicate that Alcα plays a physiologically relevant role in APP metabolism to ameliorate AD pathogenesis.

Results

Generation of Alcα-deficient mice

To evaluate the role of Alcα in endogenous APP metabolism, Alcα-deficient mice were generated using a standard gene knockout method with a targeting vector in which the coding sequence of exon 1 was replaced with the LacZ-pA-PGK-Neo-pA cassette (Fig. 1A). Mutant mice carrying the allele without pGKNeo were backcrossed with C57BL/6 mice over 10 generations. The mutation was confirmed by Southern blotting and PCR analysis (Fig. 1, B and C). The absence of Alcα protein was confirmed by immunoblotting and immunostaining (Fig. 1, D and E) of brain extracts and slices with specific antibodies, as Alcα is predominantly expressed in brain tissue (20). Two bands representing full-length Alcα and Alcα C-terminal fragment (CTF), which is the cytoplasmic CTF generated following the cleavage of Alcα by APP α-secretase (ADAM10/17), were detected with antibodies that recognized the carboxyl cytoplasmic region of Alcα in the WT (+/+) mouse brains (20, 23, 26). Neither band was detected in the brains of knockout (−/−) mice (Fig. 1D). Alcα was expressed in whole-brain tissue with a stronger expression in the hippocampal neurons of WT (+/+ ) mice, based on immunohistochemical staining; these signals were not detected in knockout (−/−) mice (Fig. 1E). These results indicate that homozygous mutant mice expressed neither the full-length Alcα nor the truncated/processed fragments of Alcα.

Alcα deficiency enhances cleavages of APP by β-secretase but not α-secretase

APP is primarily cleaved by either α- or β-secretase to generate APP CTFs. The α-cleavage of APP generates C83/CTFα by cleaving the peptide bond between Lys-687 and Leu-688 (sequence numbering refers to the APP770 isoform) within the Aβ sequence. Thus, this cleavage is amyloidogenic. Alternatively, β-cleavage of APP generates C99/CTFβ by cleaving the peptide bond between Met-671 and Asp-672 and generates C89/CTFβ’ by cleaving the peptide bond between Tyr-681 and Gln-682 (27, 33). We examined whether defects in Alcα would influence the primary cleavages of APP in vivo (Fig. 2). The cerebral cortex and hippocampus membrane fractions, prepared from WT (+/+ ) and Alcα-KO (−/−) mice brains (3 months old), were analyzed for Alcα expression and cleavages of APP by immunoblotting. Identical protein amounts were loaded per lane, as indicated in the figure legends, and the densities of bands were quantified following normalization using the integral membrane protein flotillin-1. Among the three major APP isoforms (amino acid numbers 770, 751, and 695), brain neurons exclusively expressed the APP695 isoform and showed three protein bands. These comprised two mature forms with different O-glycosylation with N-glycosylation and one immature form with N-glycosylation alone on an immunoblotted membrane (reviewed in Ref. 34). Maturation of APP was largely identical and a slight alteration of APP protein level was observed, however not statistically significant, between the WT (+/+ ) and knockout (−/−) mouse brains (Fig. 2 A and C) and Fig. S1). This suggests that defects in Alcα expression did not significantly affect the expression or posttranslational modification of the APP.

We next examined APP CTF levels in the brains of these mice. Three CTF fragments (C99, C89, and C83) were detected and measured by immunoblotting phosphatase-treated membrane fractions prepared from the cerebral cortex and hippocampus of the indicated mice, with antibodies raised against the APP cytoplasmic region (see Fig. S1). Levels of C99 and C89, generated by β-cleavage of APP, were significantly increased in Alcα-KO mouse brains compared with WT mice. Levels of C83, generated by α-cleavage of APP, were not altered among the brains of WT and Alcα-deficient mice (Fig. 2, B and C). These results indicate that the β-site cleavage of APP was enhanced in the brains of Alcα-deficient mice. We further examined age-specific alterations of the enhanced β-site cleavage in Alcα-KO mice. Selective enhancement of β-site cleavage in Alcα-KO mice was observed from 2-month-old adult mice (Fig. S1). The ratio of β-site cleavage enhancement was virtually unaltered with age. The observed enhancement of β-site cleavage in Alcα-KO mice was probably not due to the augmented expression of BACE1, as no statistically significant alteration of BACE1 expression was observed between the WT and Alcα-deficient mouse brains (see Fig. 4A).

Enhanced β-site cleavage of APP should induce increased Aβ generation as APP CTFs are subject to secondary cleavage by γ-secretase that generates Aβ and p3 peptides. We next quantified the endogenous Aβ levels in the brains of WT and
Alcα-deficient mice (Fig. 2D). Mouse Aβ is largely recovered into a TBS-insoluble fraction, regardless of its nonaggregative nature (17). We thus examined Aβ40 and Aβ42 levels in TBS-insoluble fractions of the hippocampus and cerebral cortex of WT and Alcα-deficient mice at ages 2, 6, and 12 months. Endogenous mouse Aβ40 and Aβ42 levels were significantly increased in the brains of Alcα-deficient mice (filled columns) compared with the WT mice (open columns). The enhancements were roughly comparable with those of the enhanced production of Aβ peptides at the corresponding ages. As stated earlier, endogenous mouse Aβ is less aggregation-prone than the human Aβ, and it is rather natural to not observe significant age-related accumulation of mouse Aβ in these mice. Taken together, these results indicate that Alcα may functionally suppress amyloidogenic β-cleavage of APP in the brain.

Mouse Aβ does not form amyloid plaques due to its nonaggregative nature (33), and the mouse endogenous Aβ peptides did not accumulate in their brains with age, as shown in Fig. 2D. Hence, it is unclear whether Alcα deficiency would be sufficient to contribute to plaque formation that characterizes AD pathology. Therefore, we crossed Alcα-deficient mice with APP23 human APP-transgenic mice to generate APP23/Alcα-deficient mice and examined brain amyloid plaque formation (Fig. 3). Brain slices (10 35-μm-thick slices with 350-μm intervals, −2.8 to +0.7 mm to bregma) of these mice (12 months old) were immunostained with an anti-Alcα antibody and anti-actin antibody. * nonspecific product. E, immunostaining of sagittal sections of WT (+/+) and homozgyous mutant (−/−) mouse (2–3 months old) brains with the anti-Alcα antibody. Scale bar, 1 mm.
Alcα-deficient mice were quantified, including the cerebral cortex, hippocampus, and entorhinal cortex. The numbers of plaques and proportion of plaque area were significantly higher in APP32/Alcα-deficient mice than in APP23/Alcα-deficient mice (Fig. 3C), implying that Alcα ameliorates AD pathogenesis and that Alcα deficiency augments amyloid plaque formation.

**Alcβ deficiency does not affect APP metabolism**

Alcα has closely related family members alcadein β/calsyn- tenin 3 (Alcβ) and alcadein γ/calsyn-tenin 2 (Alcγ). Alcβ is also highly expressed in the brain (Fig. S2D). It is therefore plausible that Alcβ may also be involved in amyloidogenic processing of APP. To address this question, we generated Alcβ-deficient mice by replacing exons 1–3 with the PGKNeo cassette (Fig. S2A) and verified their APP metabolism in vivo (6 months old) (Fig. 4). As demonstrated in Fig. 2, Alcα deficiency significantly augmented amyloidogenic processing of endogenous APP and subsequent generation of Aβ-peptides, without affecting BACE1 levels (Fig. 4, A and B). However, Alcβ-deficient mice did not show any significant differences in APP metabolism or Aβ peptide generation (Fig. 4, A and B). Alcβ deficiency did not augment amyloidogenic processing in an Alcα-deficient background, even in older (12-month-old) mice (Fig. S3), suggesting that Alcβ likely plays a different role in Alzheimer’s disease pathobiology in vivo. Therefore, we focused our subsequent analyses on Alcα.

**Alcα deficiency attenuates APP-X11L association to enhance APP β-site cleavage in endosomes**

Our previous reports indicated that X11L deficiency increases β-site cleavage of APP in the brain due to the lack of association between APP and X11L (16, 17). Alcα is also identified as an X11L-binding protein and forms a complex with APP, mediated by X11L. Furthermore, the interaction between APP and X11L is enhanced by the association of Alcα with X11L in vitro (20). Alcα and X11L were co-immunoprecipitated with anti-APP antibody from mouse brain lysate and were found to be co-localized in the hippocampus (20). To further confirm the co-expression of APP, Alcα, and X11L in neurons, we performed triple labeling of single primary cultured cortical neurons with mouse anti-X11L, rabbit anti-APP, and guinea pig anti-Alcα antibodies (20, 35, 36). Co-localization was readily observed for these proteins, especially around the perinuclear structures in neurons (Fig. S4). We therefore postulated that the association of APP with X11L would be attenuated by Alcα deficiency in the brain. To examine this possibility, we performed a co-immunoprecipitation assay of APP with X11L in the brain (hippocampus and cerebral cortex) lysates of WT and Alcα-deficient mice (Fig. 5). Anti-X11L antibody recovered APP along with X11L from solubilized brain membranes of WT (+/+) and Alcα-deficient (−/−) mice. A smaller amount of APP was recovered from the brains of Alcα-deficient mice compared with the WT, indicating that the association of APP with X11L was attenuated in the brains of Alcα-deficient mice. These results supported the idea that the failure to form a tripartite complex comprising of APP, X11L, and Alcα in the brains of Alcα-deficient mice increased the β-site cleavage of APP by BACE1.

BACE1 is active in the acidic compartment of the endosomal pathway, and CTFβ and CTFβ′ are largely generated in endosomes (27, 37). Therefore, we examined whether the β-site cleavage of APP was facilitated in endosome-enriched fractions from the brains of Alcα-deficient mice (Fig. 6). Endosome-enriched fractions of the brain were prepared by ultracentrifugation of the post-nuclear supernatant of the brain homogenate with a discontinuous sucrose gradient solution (Fig. 6A). A typical fractionation profile of a WT mouse brain is shown in Fig. 6.
6B. 10% of post-nuclear proteins were recovered in the endosome-enriched fraction (fraction 5), and others containing cytoplasmic proteins were recovered in fractions 9 and 10 (Fig. S5). EEA1, a cytoplasmic protein associating with early endosomes through phosphatidylinositol 3-phosphate, and BACE1 were readily detected in the endosome-enriched fraction. The majority of APP CTFs were recovered in the endosome-enriched fractions of WT (+/+) and Alcα-deficient (−/−) mouse brains (Fig. 6C) and were examined and compared with the endosome-subtracted fractions. Greater amounts of CTFβ/C99 and CTFβ'/C89 were recovered from the endosome-enriched fractions of Alcα-deficient mouse brains than from the WT mouse brains. The amounts of APP CTFs of other protein fractions were not significantly different between the WT and Alcα-KO mouse brains (Fig. 6, C and D). These results suggest that APP cleavage at the β-sites in endosomes was facilitated in the brains of Alcα-KO mice, thus supporting the notion that the presence of Alcα attenuates APP cleavage by BACE1.

Discussion

In this study, we explored the role of Alcα in the amyloidogenic metabolism of APP, especially in the regulation of β-site cleavage of APP, in brains in vivo using Alcα gene KO mice. The generation and neurotoxic oligomer formation of Aβ in the brain causes neurodegeneration and promotes the onset of Alzheimer’s disease, the most common neurodegenerative disease of aged subjects (38–40). Therefore, precise elucidation of the mechanisms regulating Aβ generation in the brain will be crucial to understand AD pathogenesis and inform therapeutic development. We demonstrated that Alcα is involved in the regulation of amyloidogenic processing of endogenous APP, and Alcα deficiency sufficiently augments Aβ generation to enhance amyloid plaque formation in human APP-Tg mice, with a reduced association of X11L with APP.

The neuronal adaptor protein X11L is a regulator of β-site cleavage of APP, and X11L forms a complex with APP and Alcα. The presence of the tripartite complex comprising APP, X11L, and Alcα has been demonstrated in mouse brains by co-immunoprecipitation (20). Our observations strongly support the idea that the tripartite complex formation is a physiologically relevant step that affects APP metabolism.

The present study using Alcα-deficient mice clearly demonstrated that in Alcα-deficient brains, (i) β-site cleavages of APP
Alcadelin α deficiency enhances APP amyloidogenic processing

A, immunoblot analysis of APP CTFs in Alcα- or Alcβ-deficient mice. A total of 15 μg of membrane fraction of the hippocampus and cerebral cortex of WT (+/+ and homozygous mutant (−/−) mice (6 months old) were analyzed in 15% resolving gel with anti-APP and anti-synaptophysin (SYP) antibodies. The same fractions were also analyzed in an 8% resolving gel with anti-Alcα, anti-Alcβ, anti-BACE1, and anti-flotillin-1 antibodies. B, band densities of APP CTFs for WT (black columns) and Alcα- or Alcβ-deficient (colored columns as indicated) were standardized to the density of synaptophysin, and the value of WT was assigned a reference value of 1.0. CTF9, CTFβ; C89, CTFβ9; C83, CTFα of APP CTFs (n = 4 mice/group; two-way ANOVA; Dunnett’s post hoc test compared with WT; *, p < 0.05; **, p < 0.01). Band densities of APP (m, mature APP; im, immature APP; t, total APP) and BACE1 were also quantified and standardized to the density of flotillin-1, and the value of WT was assigned a reference value of 1.0. Error bars, S.E. C, endogenous mouse Aβ40 or Aβ42 in the hippocampus and cerebral cortex of WT (open column) and Alcα- or Alcβ-deficient (colored columns as indicated) mice were quantified using sandwich ELISA. The Aβ40 and Aβ42 concentrations were normalized to tissue weight (n = 4 mice/group; one-way ANOVA; Dunnett’s post hoc test compared with WT; *, p < 0.05; ***, p < 0.001). Error bars, S.E.

Figure 4. Alcα-, but not Alcβ-deficient mice showed significant alterations in amyloidogenic processing of APP. A, immunoblot analysis of APP CTFs in Alcα- or Alcβ-deficient mice. A total of 15 μg of membrane fraction of the hippocampus and cerebral cortex of WT (+/+ and homozygous mutant (−/−) mice (6 months old) were analyzed in 15% resolving gel with anti-APP and anti-synaptophysin (SYP) antibodies. The same fractions were also analyzed in an 8% resolving gel with anti-Alcα, anti-Alcβ, anti-BACE1, and anti-flotillin-1 antibodies. B, band densities of APP CTFs for WT (black columns) and Alcα- or Alcβ-deficient (colored columns as indicated) were standardized to the density of synaptophysin, and the value of WT was assigned a reference value of 1.0. CTF9, CTFβ; C89, CTFβ9; C83, CTFα of APP CTFs (n = 4 mice/group; two-way ANOVA; Dunnett’s post hoc test compared with WT; *, p < 0.05; **, p < 0.01). Band densities of APP (m, mature APP; im, immature APP; t, total APP) and BACE1 were also quantified and standardized to the density of flotillin-1, and the value of WT was assigned a reference value of 1.0. Error bars, S.E. C, endogenous mouse Aβ40 or Aβ42 in the hippocampus and cerebral cortex of WT (open column) and Alcα- or Alcβ-deficient (colored columns as indicated) mice were quantified using sandwich ELISA. The Aβ40 and Aβ42 concentrations were normalized to tissue weight (n = 4 mice/group; one-way ANOVA; Dunnett’s post hoc test compared with WT; *, p < 0.05; ***, p < 0.001). Error bars, S.E.

Alcadein α deficiency enhances APP amyloidogenic processing

J. Biol. Chem. (2020) 295(28) 9650–9662
9655

A

B

C

Murine Aβ40

Murine Aβ42

Figure 4. Alcα-, but not Alcβ-deficient mice showed significant alterations in amyloidogenic processing of APP. A, immunoblot analysis of APP CTFs in Alcα- or Alcβ-deficient mice. A total of 15 μg of membrane fraction of the hippocampus and cerebral cortex of WT (+/+ and homozygous mutant (−/−) mice (6 months old) were analyzed in 15% resolving gel with anti-APP and anti-synaptophysin (SYP) antibodies. The same fractions were also analyzed in an 8% resolving gel with anti-Alcα, anti-Alcβ, anti-BACE1, and anti-flotillin-1 antibodies. B, band densities of APP CTFs for WT (black columns) and Alcα- or Alcβ-deficient (colored columns as indicated) were standardized to the density of synaptophysin, and the value of WT was assigned a reference value of 1.0. CTF9, CTFβ; C89, CTFβ9; C83, CTFα of APP CTFs (n = 4 mice/group; two-way ANOVA; Dunnett’s post hoc test compared with WT; *, p < 0.05; **, p < 0.01). Band densities of APP (m, mature APP; im, immature APP; t, total APP) and BACE1 were also quantified and standardized to the density of flotillin-1, and the value of WT was assigned a reference value of 1.0. Error bars, S.E. C, endogenous mouse Aβ40 or Aβ42 in the hippocampus and cerebral cortex of WT (open column) and Alcα- or Alcβ-deficient (colored columns as indicated) mice were quantified using sandwich ELISA. The Aβ40 and Aβ42 concentrations were normalized to tissue weight (n = 4 mice/group; one-way ANOVA; Dunnett’s post hoc test compared with WT; *, p < 0.05; ***, p < 0.001). Error bars, S.E.

Alcadein α deficiency enhances APP amyloidogenic processing

J. Biol. Chem. (2020) 295(28) 9650–9662
9655

to generate CTFβ/C99 and CTFβ9/C89 were significantly enhanced, (ii) Aβ generation was significantly increased, (iii) AD pathology progressed in human APP-Tg mice, and (iv) association of APP with X11L was also attenuated. Although the role of Alcα in the amyloidogenic cleavage of APP is an indirect effect mediated by X11L, these results indicate that Alcα plays an important role in the regulation of APP amyloidogenic metabolism in the brain. Our previous observations suggested that one function of X11L is to prevent APP from being transported into membrane microdomains in which active BACE1 resides (17). Our present analyses suggest that Alcα enhances the functions of X11L by forming a tripartite complex comprising APP, X11L, and Alcα; the absence of Alcα may facilitate localization of APP in these membrane microdomains, including in endosomes. The mechanism underlying the formation of the tripartite complex that prevents APP subcellular localization and enhances its amyloidogenic processing is yet to be elucidated. Sortilin and its related family members affect APP subcellular localization through their direct interaction with APP to modulate amyloidogenic processing of APP (reviewed in Ref. 41). The tripartite complex formation could affect their accessibility to APP in a manner attenuating its amyloidogenic processing. It would also be plausible that the tripartite complex formation may prevent APP from being sorted to endocytic pathway in Golgi apparatus. APP and Alcα have similar functions as the cargo receptor molecule of kinesin-1 in neurons (35, 42, 43). Transport membrane vesicles, including APP, bind to kinesin-1 via the cytoplasmic region of APP; this binding is mediated by c-Jun N-terminal kinase–interacting protein 1 (JIP1) interaction between APP and kinesin light chain of kinesin-1, by which APP vesicles are anterogradely transported with high efficiency in axons (43–45). Alcα also associates with kinesin light chain of kinesin-1 directly, using its cytoplasmic WD motifs, by which transport membrane vesicles, including Alcα, transport cargos toward nerve terminals, as does APP (35, 42). Transport cargos of Alcα are
Alc"a deficiency enhances APP amyloidogenic processing

![Image of a figure with two panels: A, co-immunoprecipitation of APP with X11L in the presence or absence of Alc"a. Crude membrane fractions (500 μg of protein) of the hippocampus and cerebral cortex of WT (+/+) and Alc"a-deficient (−/−) mice were subject to immunoprecipitation with anti-X11L antibody, and the immunoprecipitates were analyzed by immunoblotting with anti-APP, anti-X11L, and anti-Alc"a antibodies. B, the band densities of APP in A were quantified and standardized against X11L in the immunocomplex. APPs, mature APP plus immature APP; imAPP, immature APP; mAPP, mature APP. WT was assigned a reference value of 1.0. Statistical significance was analyzed using three independent experiments (n = 3 mice/group; unpaired t test; * p < 0.05; ** p < 0.01). Data represent means ± S.E. (error bars).

Figure 5. Attenuated association of APP with X11L in the brains of Alcα-deficient mice. A, co-immunoprecipitation of APP with X11L in the presence or absence of Alcα. Crude membrane fractions (500 μg of protein) of the hippocampus and cerebral cortex of WT (+/+) and Alcα-deficient (−/−) mice were subject to immunoprecipitation with anti-X11L antibody, and the immunoprecipitates were analyzed by immunoblotting with anti-APP, anti-X11L, and anti-Alcα antibodies. B, the band densities of APP in A were quantified and standardized against X11L in the immunocomplex. APPs, mature APP plus immature APP; imAPP, immature APP; mAPP, mature APP. WT was assigned a reference value of 1.0. Statistical significance was analyzed using three independent experiments (n = 3 mice/group; unpaired t test; * p < 0.05; ** p < 0.01). Data represent means ± S.E. (error bars).

largely independent of APP cargos in functions with different transport velocity (35, 43). When the functions of either APP or Alcα cargos are impaired, they are likely to be compensated for each other’s roles to maintain neuronal function (46). Therefore, functional deficiency in Alcα may also influence neuronal function and proteolytic metabolism of APP possibly by affecting its intracellular transport and association with other factors, such as X11L. Indeed, altered function of Alcα disturbs APP axonal transport and increases the production of Aβ. Previous observations suggest that APP and Alcα may function cooperatively around Golgi exit sites (47, 48), and release of APP from X11L may be regulated by phosphorylation of X11L (49). These observations lead to the hypothesis of a possible mechanism by which Alcα and X11L collectively suppress premature dispatching of APP into the endocytic membrane traffic system. It was recently reported that activity-dependent APP endocytosis to endosome is required and enhanced by the X11 family proteins to augment Aβ production in cultured neurons (50). Given that a considerable amount of Alcα resides in the endosome-enriched fraction (Fig. 6C, and Fig. S5), it would also be plausible that X11L family proteins, free from Alcα, make APP become more efficiently internalized into the endosome in Alcα-deficient neurons. Further investigations are required to verify this. Recent analysis with integrative genomics reports that the AGBPA2 gene, which encodes X11L, is a modulator of late-onset AD (51). Although this report was retracted later (52), the integrative genomics analysis itself was not fabricated (53), and our recent observation suggested that X11L significantly affects gene expression profile in the human APOE ε4 knock-in mouse brain.6 These analyses may collectively support the idea that Alcα plays an important role in the regulation of X11L function in the AD onset. It should be noted that X11L is a family member of the X11 family proteins: X11, X11L, and X11L2. Previous studies showed that X11L is widely expressed in the brain and appears to be responsible for attenuating amyloidogenic processing of endogenous APP (16, 17, 54). However, other X11 family members are known to share the same properties in the regulation of APP metabolism (20, 50), and X11s could possess an equivalently important function in the brain, especially in the neurons predominantly expressing other family members.

Alcα is also a closely related family member of Alcs: Alcα, Alcβ, and Alcγ. Contrary to the aforementioned expectation of X11 family members, Alcβ deficiency did not augment amyloidogenic processing of APP, suggesting that Alcβ has different functions. Our recent observations suggested that Alcβ may be differently involved in AD pathogenesis in terms of p3-Alcβ peptide generation (55), which would further support this notion. Alcβ is also reported to have synaptogenic activity through association with α-neurexin; however, Alcα does not exhibit such activity (56). Alcα deficiency likely has different physiological roles despite their similar metabolisms and primary structures (20, 26).

Overall, our study provided evidence to strengthen the notion that the neuronal membrane protein Alcα is closely related to APP function and AD pathogenesis through intracellular interactions between APP and Alcα. Alcα deficiency leads to augmented amyloidogenic processing of endogenous APP in vivo. Further analysis of the roles of Alcα in APP metabolism and neurodegeneration will deepen our understanding of AD pathogenesis and contribute to novel therapeutic development for AD.

Experimental procedures

Generation of Alcα-KO, Alcβ-KO, and human APP-Tg/Alcα-KO mice

All experimental protocols were approved by the animal care and use committees of Hokkaido University, RIKEN Kobe Branch, and Kagawa University. All experiments were conducted in compliance with the ARRIVE guidelines. Mouse genomic DNA containing the first exon of the Alcα gene (CLSTN1) was obtained from a C57BL/6 BAC clone (Invitrogen) and used to construct a targeting vector. The coding sequence was replaced by a LacZ-pA-PGK-Neo-pA cassette from DT-A/LacZ/Neo plasmid to construct the targeting vector, which was electroporated into TT2 embryonic stem (ES) cells (57). The successful recombinants were identified by PCR using the primer sets 5’-ACCGCTTCTCGTGCTTTACGTTATC-3’ and 5’-TAAGAACCTATTTAACAGGGCAGCTAGC-3’ and further confirmed by Southern blotting analysis. The recombinant ES cells

---

6 T. Nakaya and T. Suzuki, unpublished observation.
Alcadein α deficiency enhances APP amyloidogenic processing

A

B

C

D

Endosome-enriched membrane (fraction 5)

Other protein (fraction 9)

D1

Endosome-enriched Other protein

Relative ratio

C99 C89 C83 APP C99 C89 C83 APP

* *
Alcadein α deficiency enhances APP amyloidogenic processing

were injected into ICR eight-cell stage embryos to generate chimeric founders, which were crossed to C57BL/6 females to obtain mice carrying the disrupted allele. The resultant mice (accession no. CDB0472K; RIKEN Center for Biosystems Research) were backcrossed to C57BL/6 mice for more than 10 generations. The PGK-Neo region of the cassette was removed by crossing to transgenic C57BL/6 mice ubiquitously expressing flippase (58). The presence of the WT allele and floxed LacZ-pA-pA allele was verified by PCR using the following primer sets: 5′-GGGCTTGGGCGCGGAGTAGA-3′ and 5′-CCACCTCCTTGCCACCGTTACTAT-3′ for WT (416 bp); 5′-CGGGTGTCGGGCCGAGGTTAA-3′ and 5′-GCTGGCTCAGCATGAAACAGTTTG-3′ for LacZ-pA-pA (1,224 bp) (see Fig. 1).

For generating Alcβ-KO mice, the genomic DNA fragment of 129Sv mice containing Alcβ exons 1–5 was isolated, and its EcoRV-EcoRI region containing exons 1–3 was replaced with the pGKneo (59) cassette. The resultant targeting vector was electroporated into ES-D3 cells, and successful recombinants were identified by Southern blotting. The recombinant ES cells were injected into ICR eight-cell stage embryos to generate chimeric founders, which were crossed to C57BL/6 females to obtain mice carrying the disrupted allele. The resultant mice were backcrossed to C57BL/6 mice for more than 10 generations. The presence of the WT allele and pGKneo allele was verified by PCR using the following primer sets: 5′-GGTACCTCTCGGACTGTGATC-3′ and 5′-GAGACTTCTTGTATTTGGTGCCACCTC-3′ for WT (158 bp); 5′-ATACCGTAAAGCAGGAGGGTGCTC-3′ and 5′-CATTGCACCACCAAGGACATGC-3′ for pGKneo (343 bp) (see Fig. S1).

The human APP751swe-tg APP23 mouse was kindly supplied from Novartis Pharma Inc. (60). APP23/Alcα-KO mice were generated by mating APP23 mice with Alcα-KO mice. Heterozygous human APPswe transgenic (Tg+/−, Alcα−/−) and (Tg+/+), Alcα +/+ mutant mice were used for experimentation.

**Immunohistochemistry**

Frozen mouse brain sections (20-μm-thick) were prepared as described previously (61). Sections were incubated with 0.1% (v/v) Triton X-100 in PBS and blocked with PBS including 5% (v/v) heat-inactivated goat serum, and then incubated with guinea pig polyclonal anti-Alcα antibody (col90, 1:200 dilution) (36), mouse monoclonal anti-X11L (MINT2, 1:250 dilution, BD Biosciences), and rabbit anti-APP (G369, 1:100 dilution) (17) followed by a secondary incubation with anti-rabbit IgG Alexa Fluor 488, anti-mouse IgG Alexa Fluor 633 (Invitrogen), and anti-guinea pig IgG Cy3 (Jackson ImmunoResearch Laboratories). After washing the sections with PBS, the sections were mounted using Shandon Immuzu-Mount (catalog no. 9990402, Thermo Fisher Scientific), observed by fluorescence microscopy with a ×63 objective and a ×10 eyepiece lens, and then merged into respective images (BZ-9000, Keyence). Specificities of antibodies were verified using corresponding deficient mice whenever possible (see Fig. 1E and Fig. S2D).

**Measurement of Aβ plaque load**

APP23 mouse brains were fixed and sliced to prepare 35-μm-thick sections (−2.8 to +0.7 mm to bregma), and 10 slices per brain with a 315-μm interval were further processed. The slices were incubated in PBS containing 0.3% (v/v) hydrogen peroxide, washed in PBS three times, and incubated in PBS containing 70% (v/v) formic acid for 1 min prior to blocking. The sections were incubated with mouse monoclonal anti-human Aβ 82E1 antibody (1 μg/ml; IBL, Fujioka, Japan) and washed three times for 10 min. The sections were then incubated for 1 h at room temperature with horse anti-mouse IgG conjugated with biotin (Vector Laboratories, Burlingame, CA, USA), followed by VECTASTATIN ABC kit (Vector Laboratories). Peroxidase activity was revealed using diaminobenzidine as a chromogen. The sections were viewed using a BZ-9000 microscope with a ×10 objective and ×10 eyepiece lens followed by merging of respective images (Keyence). Numbers of plaques in these 10 slices per brain were counted manually, and the resultant number was divided by the area of the slices. For measurement of the plaque area, the same images were turned to black-and-white images with ImageJ software by thresholding nonplaque signals.
Aβ levels in mouse brains

Mouse endogenous Aβ40 and Aβ42 were measured as described previously (16). Hippocampus and cortex from mice were homogenized in a 6-fold volume of TBS (50 mM Tris-HCl, pH 7.6, 150 mM NaCl) containing a protease inhibitor mixture. The homogenates were centrifuged at 200,000 × g for 20 min, and the pellet was washed in TBS at 200,000 × g for 5 min (TLA 100.4 rotor; Beckman Coulter, Brea, CA, USA), and 9.1 μl of 6 M guanidine chloride in TBS was added to the washed pellet. The pellet was sonicated for 30 s, allowed to stand for 60 min at room temperature, and subjected to centrifugation at 200,000 × g for 20 min. The supernatant was diluted with a 12-fold volume of ELISA buffer (PBS containing 0.05% (v/v) Tween 20 and 1% (w/v) BSA) and centrifuged at 14,000 × g for 5 min. The resulting supernatant was used for quantification of mouse Aβ with an ELISA kit (IBL, Fujioka, Japan), catalog no. 27720 for Aβ40 and catalog no. 27721 for Aβ42.

Co-immunoprecipitation of APP and X11L from solubilized brain membrane fraction

Mouse cerebral cortex and hippocampus were homogenized (five strokes of a Dounce homogenizer) in an 8-fold volume of buffer H (20 mM HEPES (pH 7.4), 150 mM NaCl, 10% (v/v) glycerol, 5 mM EDTA) containing a protease inhibitor mixture. The homogenate was centrifuged at 1,000 × g for 10 min at 4 °C. The supernatant was subjected to ultracentrifugation at 100,000 × g (TLA-55 rotor; Beckman Coulter) for 1 h at 4 °C, and the resultant precipitates (P100 fraction) were used for immunoblot analysis. The indicated amounts of proteins were separated by SDS-PAGE (8% (w/v) polyacrylamide Tris-glycine gels for APP, Alcα, Alcβ, BACE1, and X11L; 12% (w/v) polyacrylamide Tris-glycine gels for BACE1 (Fig. 4A); or 15% (w/v) polyacrylamide Tris-Tricine gels for APP CTF and Alcα CTF, which are carboxyl-terminal fragments of APP and Alcα cleaved by α- or β-secretase, respectively). To identify APP CTFβ/C99, CTFβ’/C89, and CTFα/ C83 precisely, samples were treated with a protein phosphatase (400 units; Sigma–Aldrich) for 2 h as phosphorylation of APP CTFs at Thr-668 (amino acid number for APP695 isoform) causes the complex protein pattern on immunoblotting (62, 63) (reviewed in Ref. 34) (see Fig. S1). The separated proteins were transferred onto a nitrocellulose membrane and probed with primary antibodies. Immuneoreactive proteins were detected using Clarity Western ECL substrate (catalog no. 170-5061, Bio-Rad) and quantitated on LAS-4000 (FUJIFILM, Tokyo, Japan). Rabbit polyclonal anti-Alcα UT83 (1:500) (20), anti-Alcβ UT99 (1:500) (11), anti-APP 369 (1:4,000) (64), and anti-BACE1 Ab-2 (1:1,000) (Millipore, Burlington, MA, USA) antibodies; rabbit monoclonal anti-BACE1 D10E5 (for Fig. 4A and B), 1:1,000; Cell Signaling Technology, Danvers, MA, USA); and mouse monoclonal anti-actin (1 μg/ml; Chemicon International, Temecula, CA, USA), anti-X11L Mint2 (1:1,000, BD Transduction Laboratories/BD Bioscience), anti-α-tubulin (1:10,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-flotillin-1 (1:1,000; BD Transduction Laboratories), anti-EAA1 (1:10,000; Santa Cruz Biotechnology), and anti-transporter receptor (1:1,000, BD Transduction Laboratories) were as described or purchased. Results were derived from multiple independent experiments. The numbers of experiments (n) are indicated in the figure legends. Specificities of antibodies were verified using corresponding deficient mice whenever possible (see Figs. 1D and 4A).

Preparation of endosome-enriched fraction

The cerebral cortex and hippocampus of mouse brains were homogenized (30 strokes of Dounce homogenizer) in an 8-fold volume of solution (0.25 M sucrose, 3 mM imidazole, pH 7.5) and subjected to centrifugation at 1,000 × g for 10 min at 4 °C. The resultant supernatant (1 ml) was suspended in 2 ml of buffer (final 42.5% sucrose, 3 mM imidazole) in a centrifugation tube (Beckman Coulter PA13.2) and mixed. Solutions of 35 and 8% sucrose containing 3 mM imidazole, respectively, were layered in the tube, and the sample was subjected to centrifugation at 35,000 rpm for 3 h at 4 °C (SW41 Ti rotor, Beckman Coulter). Samples were collected with a 1-ml fraction from top to bottom. Fraction 5 (Fig. 6, fr. 5), including the interface between 35 and 8% sucrose density solution, was recovered as the
Alcaldelin α deficiency enhances APP amyloidogenic processing

endosome-enriched fraction along with fraction 9 (fr. 9), containing other membranes with cytoplasmic proteins (65). An equal volume of solution (0.25 mM sucrose/3 mM imidazole) was added to both fractions and centrifuged at 100,000 × g for 1 h at 4°C (TLA-55 rotor, Beckman Coulter). Resultant precipitates were analyzed for immunoblotting.

Statistical analysis
Data are expressed as means ± S.E. Statistical differences were assessed using unpaired two-tailed Student’s t tests for two comparisons and two-way nonrepeated measures ANOVA with Tukey’s post hoc test for multiple comparisons. A p value of <0.05 was considered statistically significant. No sample size calculation, tests for normal distribution, or tests for outliers were performed. The study was not preregistered.

Data availability
All data described are contained in the article and the supporting information.

Author contributions—N. G., Y. S., S. H., H. S., D. O., C. M., T. S., and T. Y. formal analysis; N. G., Y. S., T. S., and T. Y. investigation; Y. S., T. S., and T. Y. writing-review and editing; S. H., T. A., D. K., F. M., T. S., and T. Y. supervision; M. S., T. A., D. K., F. M., and T. Y. conceptualization; S. H., T. S., and T. Y. funding acquisition; T. S. and T. Y. writing-original draft; T. S. and T. Y. project administration; T. S. and T. Y. methodology.

Funding and additional information—This work was supported in part by KAKENHI, Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) JP18K07384 (to S. H.); JP26293010 and JP18H02566 (to T. S.); and JP25460059, JP16K08237, and JP19K07065 (to T. Y.) and by Strategic Research Program for Brain Sciences from the Japan Agency for Medical Research and Development Grant JP19dm0107142h0004.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: AD, Alzheimer’s disease; APP, amyloid β protein precursor; BACE1, β-site APP-cleaving enzyme 1; Aβ, amyloid β protein; CTF, C-terminal fragment; Alc, alcaldelin; SYP, synaptophysin; TBS, Tris-buffered saline; X11L, X11-like; KO, knockout; ES, embryonic stem; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; ANOVA, analysis of variance; Tg, transgenic.

References
1. Takami, M., and Funamoto, S. (2012) γ-Secretase-dependent proteolysis of transmembrane domain of amyloid protein precursor: successive tri- and tetrapeptide release in amyloid β protein production. Int. J. Alzhei- mers Dis. 2012, 591392 CrossRef Medline
2. Kakuda, N., Shoji, M., Arai, H., Furukawa, K., Ikeuchi, T., Akazawa, K., Takami, M., Hatsuta, H., Murayama, S., Hashimoto, Y., Miyajima, M., Arai, H., Nagashima, Y., Yamaguchi, H., Kuwano, R., et al. (2012) Altered γ-secretase activity in mild cognitive impairment and Alzheimer’s disease. EMBO Mol. Med. 4, 344–352 CrossRef Medline
3. Forman, M. S., Cook, D. G., Leighton, S., Doms, R. W., and Lee, M.-Y. V. (1997) Differential effects of the Swedish mutant amyloid precursor protein on β-amyloid accumulation and secretion in neurons and nonneuroonal cells. J. Biol. Chem. 272, 32247–32253 CrossRef Medline
4. Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilis, L., Winblad, B., and Lannfelt, L. (1992) A pathogenic mutation for probable Alzheimer’s disease in the APP gene at N-terminus of β-amyloid. Nat. Genet. 1, 345–347 CrossRef Medline
5. Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., Mant, R., Newton, P., Rooke, K., Roques, P., Talbot, C., et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349, 704–706 CrossRef Medline
6. Hashimoto, T., Adams, K. W., Fan, Z., McLean, P. J., and Hyman, B. T. (2011) Characterization of oligomer formation of amyloid-β peptide using a split-luciferase complementation assay. J. Biol. Chem. 286, 27081–27091 CrossRef Medline
7. Nilsberth, C., Westlund-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkun, S. G., Näslund, J., and Lannfelt, L. (2001) The “Arctic” APP mutation (E693G) causes Alzheimer’s disease by enhanced Aβ protifibril formation. Nat. Neurosci. 5, 887–893 CrossRef Medline
8. Tew, J., and Goate, A. M. (2017) Genetics of β-amyloid precursor protein in Alzheimer’s disease. Cold Spring Harb. Perspect. Med. 7, 004539 CrossRef Medline
9. Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., Goate, A. M., Bales, K. R., Paul, S. M., Bateman, R. J., and Holtzman, D. M. (2011) Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 3, 89ra57 CrossRef Medline
10. Iwata, N., Tsubuki, T., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., Gerard, C., Hama, E., Lee, H. I., and Saído, T. C. (2001) Metabolic regulation of brain Aβ by nephrilysin. Science 292, 1550–1552 CrossRef Medline
11. Vekrellis, K., Ye, Z., Qin, W.-Q., Walsh, D., Hartley, D., Cheseau, V., Rosner, M. R., and Selkoe, D. J. (2000) Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20, 1657–1665 CrossRef Medline
12. Kakuda, N., Yamaguchi, H., Akazawa, K., Hata, S., Suzuki, T., Hatsuta, H., Murayama, S., Funamoto, S., and Ihara, Y. (2020) γ-Secretase activity is associated with Braak senile plaque stages. Am. J. Pathol. 190, 1323–1331 CrossRef Medline
13. Hata, S., Hu, A., Piao, Y., Nakaya, T., Taru, H., Morishima-Kawashima, M., Murayama, S., Nishimura, M., and Suzuki, T. (2020) Enhanced amyloid-β generation by γ-secretase complex in detergent-resistant membrane microdomain accompanied by the reduced cholesterol level. Human. Mol. Genet. 29, 382–393 CrossRef Medline
14. Tomita, S., Ozaki, T., Taru, H., Oguchi, S., Takeda, S., Yagi, Y., Sakiyama, S., Kiriho, Y., and Suzuki, T. (1999) Interaction of a neuron-specific protein containing PDZ domains with Alzheimer’s amyloid precursor protein. J. Biol. Chem. 274, 2243–2254 CrossRef Medline
15. McLoughlin, D. M., Irving, N. G., Brownlee, J., Brion, J. P., Leroy, K., and Miller, C. C. (1999) Mint2/X11-like colocalizes with the Alzheimer’s disease amyloid precursor protein and is associated with neuritic plaques in Alzheimer’s disease. Eur. J. Neurosci. 11, 1988–1994 CrossRef Medline
16. Sano, Y., Syuzo-Takahatake, A., Nakaya, T., Saito, Y., Tomita, S., Itohara, S., and Suzuki, T. (2006) Enhanced amyloidogenic metabolism of the amyloid β protein precursor in the X11- deficient mouse brain. J. Biol. Chem. 281, 37853–37860 CrossRef Medline
17. Saito, Y., Sano, Y., Vassar, R., Gandy, S., Nakaya, T., Yamamoto, T., and Suzuki, T. (2008) X11 proteins regulate the translocation of Amyloid β-protein precursor (APP) into detergent-resistant membrane and suppress the amyloidogenic cleavage of APP by β-site-cleaving enzyme in brain. J. Biol. Chem. 283, 35763–35771 CrossRef Medline
18. Kondo, M., Shiono, M., Itoh, G., Takei, N., Matsushima, T., Maeda, M., Taru, H., Hata, S., Yamamoto, T., Saito, Y., and Suzuki, T. (2010) Increased amyloidogenic processing of transgenic human APP in X11-like deficient mouse brain. Mol. Neurodegener. 5, 35 CrossRef Medline
25. Portelius, E., Durieu, E., Bodin, M., Manousopoulou, A., Koslowski, S., Vasylieva, N., Barnych, B., Hammock, B. D., Bohl, B., Koch, P., Omori, C., Yamamoto, K., Hata, S., Suzuki, T., Karg, F., et al. (2018) Induction of amyloid-β42 production by fipronil and other pyrazole insecticides. J. Alzheimer's Dis. 62, 1663–1681 CrossRef Medline

26. Hata, S., Fujishige, S., Araki, Y., Kato, N., Araseki, M., Nishimura, M., Hartmann, D., Saffig, P., Fahrenholz, F., Taniguchi, M., Urakami, K., Akatsu, H., Martins, R. N., Yamamoto, K., Maeda, M., et al. (2009) Alkalinecleavages by APP α- and γ-secretases generate small peptides p3-Alcs indicating Alzheimer disease-related γ-secretase dysfunction. J. Biol. Chem. 284, 30624–30633 CrossRef Medline

27. Cole, S. L., and Vassar, R. (2008) The role of amyloid precursor protein processing by BACE1, the β-secretase, in Alzheimer’s disease pathophysiology. J. Biol. Chem. 283, 29621–29625 CrossRef Medline

28. Hata, S., Fujishige, S., Araki, Y., Taniguchi, M., Urakami, K., Peskind, E., Akatsu, H., Araseki, M., Yamamoto, K., Martins, R. N., Maeda, M., Nishimura, M., Levey, A., Chung, K. A., Montine, T., and Ukita, S. (2011) Alternative γ-secretase processing of γ-secretase substrates in common forms of mild cognitive impairment and Alzheimer disease: evidence for γ-secretase dysfunction. Ann. Neurol. 69, 1026–1031 CrossRef Medline

29. Konno, T., Hata, S., Hamada, Y., Horiokoshi-Sakuraba, Y., Nakaya, T., Saito, Y., Yamamoto, T., Yamamoto, M., Maeda, M., Ikeuchi, T., Gandy, S., Akatsu, H., and Suzuki, T. (2012) Utility of plasma levels of soluble p3-Alcadain α as a biomarker for sporadic Alzheimer’s disease. J. Alzheimers Dis. 31, 421–428 CrossRef Medline

30. Hata, S., Taniguchi, M., Piao, Y., Ikeuchi, T., Fagan, A. M., Holtzman, D. M., Bateman, R., Sohrabi, H. R., Martins, R. N., Gandy, S., Urakami, K., and Suzuki, T., and Japanese Alzheimer’s Disease Neuroimaging Initiative (2012) Multiple γ-secretase product peptides are coordinately increased in concentration in the CSF of a subgroup of sporadic Alzheimer’s disease subjects. Mol. Neurodegener. 7, 16 CrossRef Medline

31. Omori, C., Kaneko, M., Nakajima, E., Akatsu, H., Haragai, M., Maeda, M., Morishima-Kawashima, M., Saito, Y., Nakaya, T., and Suzuki, T., and Japanese Alzheimer’s Disease Neuroimaging Initiative (2014) Increased levels of plasma p3-Alca35, a major fragment of Alcadain by β-secretase cleavage, in Alzheimer’s disease. J. Alzheimers Dis. 39, 861–870 CrossRef Medline

32. Kimura, A., Hata, S., and Suzuki, T. (2016) Alternative selection of β-site APP cleaving enzyme 1 (BACE1) cleavage sites in amyloid β-protein precursor (APP) harboring protective and pathogenic mutations within the ABβ sequence. J. Biol. Chem. 291, 24041–24053 CrossRef Medline

33. Suzuki, T., and Nakaya, T. (2007) The novel cargo Alcadain induces vesicle association of kinesin-1 motor components and activates axonal transport. EMBO J. 26, 1475–1486 CrossRef Medline

34. Maruta, C., Saito, Y., Hata, S., Gottoh, N., Suzuki, T., and Yamamoto, T. (2012) Constitutive cleavage of the single-pass transmembrane protein Alcadain prevents aberrant peripheral retention of kinesin-1. PLoS ONE 7, e43058 CrossRef Medline

35. Huse, J. T., Kangning, L., Pijak, D. S., Carlin, D., Lee, V. M.-Y., and Doms, R. W. (2002) Beta-secretase processing in the trans-Golgi network preferentially generated truncated amyloid specific that accumulate in Alzheimer’s disease brain. J. Biol. Chem. 277, 16278–16284 CrossRef Medline

36. Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., and Rogers, J. (1999) Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Ann. N. Y. Acad. Sci. 886, 806–866 CrossRef Medline

37. Lesne, S. E., Sherman, M. A., Grant, M., Koskowitz, M., Schneider, J. A., Bennett, D. A., and Asher, K. H. (2013) Brain amyloid-β oligomers in aging and Alzheimer’s disease. Brain 136, 1383–1398 CrossRef Medline

38. Eggert, S., Thomas, C., Kins, S., and Hermey, G. (2018) Trafficking in Alzheimer’s disease: modulation of APP transport and processing by the transmembrane proteins LR1P, SorLA, SorCS1, Sortilin, and Calsyntenin. Mol. Neurobiol. 55, 5809–5829 CrossRef Medline

39. Kawanou, T., Araseki, M., Araki, Y., Kinjo, M., Yamamoto, T., and Suzuki, T. (2012) A small peptide sequence is sufficient for initiating kinesin-1 activation through part of TPR region of KLC1. Traffic 13, 834–848 CrossRef Medline

40. Chiba, K., Araseki, M., Nozawa, K., Furukori, K., Araki, Y., Matsumiya, T., Nakaya, T., Hata, S., Saito, Y., Uchida, S., Okada, Y., Nairn, A. C., Davis, R. J., Yamamoto, T., Kinjo, M., et al. (2014) Quantitative analysis of APP axonal transport in neurons—role of JIP1 in APP anterograde transport. Mol. Biol. Cell 25, 3569–3580 CrossRef Medline

41. Chiba, K., Chien, K., Sobi, Y., Hata, S., Kato, S., Nakaya, T., Okada, Y., Nairn, A. C., Kinjo, M., and Suzuki, T. (2017) Phosphorylation of KLC1 modifies interaction with JIP1 and abolishes the enhanced fast velocity of APP transport by kinesin-1. Mol. Biol. Cell 28, 3857–3869 CrossRef Medline

42. Tsukamoto, M., Chiba, K., Sobi, Y., Shiraki, Y., Okumura, Y., Hata, S., Kitamura, A., Nakaya, T., Uchida, S., Kinjo, M., and Suzuki, T. (2018) The cytoplasmic region of the amyloid β-protein precursor (APP) is necessary and sufficient for the enhanced fast velocity of APP transport by kinesin-1. FEBS Lett. 592, 2716–2724 CrossRef Medline

43. Sobi, Y., Furukori, K., Chiba, K., Kinjo, A. C., Kinjo, M., Hata, S., and Suzuki, T. (2017) Phosphorylation of multiple sites within an acidic region of Alcadain α is required for kinesin-1 association and Golgi exit of Alcadain α cargo. Mol. Biol. Cell 28, 3844–3856 CrossRef Medline

44. Ludwig, A., Blume, J., Diep, T. M., Yuan, J., Mateos, J. M., Leuthäuser, K., Steuble, M., Streit, P., and Sonnereger, P. (2009) Calsyntenins mediate TGN exit of APP in a kinesin-1-dependent manner. Traffic 10, 572–589 CrossRef Medline

45. Takei, N., Sobi, Y., Kimura, A., Urano, S., Piao, Y., Araki, Y., and Suzuki, T. (2015) Cytoplasmic fragment of Alcadain α generated by regulated intramembrane proteolysis

29633
Alcadein α deficiency enhances APP amyloidogenic processing

enhances amyloid β-protein precursor (APP) transport into the late secretory pathway and facilitates APP cleavage. J. Biol. Chem. 290, 987–995 CrossRef Medline

Sakuma, M., Tanaka, E., Taru, H., Tomita, S., Gandy, S., Nairn, A. C., Nakaya, T., Yamamoto, T., and Suzuki, T. (2009) Phosphorylation of the amino-terminal region of X11L regulates its interaction with APP. J. Neurochem. 109, 466–475 CrossRef Medline

Sullivan, S. E., Dillon, G. M., Sullivan, J. M., and Ho, A. (2014) Mint proteins are required for synaptic activity-dependent amyloid precursor protein (APP) trafficking and amyloid β generation. J. Biol. Chem. 289, 15374–15383 CrossRef Medline

Rhinn, H., Fujita, R., Qiang, L., Cheng, R., Lee, J. H., and Abeliovich, A. (2013) Integrative genomics identifies APOE e4 effectors in Alzheimer's disease. Nature 500, 45–50 CrossRef Medline

Rhinn, H., Fujita, R., Qiang, L., Chen, R., Lee, J. H., and Abeliovich, A. (2015) Retraction: Integrative genomics identifies APOE e4 effectors in Alzheimer's disease. Nature 523, 626 CrossRef Medline

National Institutes of Health (2015) Findings of research misconduct, NIH Guide for Grants and Contracts (Online), NOT-OD-15-092

Motodate, R., Saito, Y., Hata, S., and Suzuki, T. (2016) Expression and localization of X11 family proteins in neurons. Brain Res. 1646, 227–234 CrossRef Medline

Hata, S., Omori, C., Kimura, A., Saito, H., Kimura, N., Gupta, V., Pedrini, S., Hone, E., Chatterjee, P., Taddei, K., Kasuga, K., Ikeuchi, T., Waragai, M., Nishimura, M., Hu, A., et al. (2019) Decrease in p3-Alcβ3 and p3-Alcβ40, products of Alcadeinβ generated by γ-secretase cleavages, in aged monkeys and patients with Alzheimer's disease. Alzheimer's Dement. (NY) 5, 748–750 CrossRef Medline

Pettem, K. L., Yokomaku, D., Luo, L., Linhoff, M. W., Prasad, T., Connor, S. A., Siddiqui, T. J., Kawabe, H., Chen, F., Zhang, L., Rudenko, G., Wang, Y. T., Brose, N., and Craig, A. M. (2013) The specific α-neurexin interactor calstennin-3 promotes excitatory and inhibitory synapse development. Neuron 80, 113–128 CrossRef Medline

Yagi, T., Tokunaga, T., Furuta, Y., Nada, S., Yoshida, M., Tsukada, T., Saga, Y., Takeda, N., Ikawa, Y., and Aizawa, S. (1993) A novel ES cell line, TT2, with high germline-differentiating potency. Anal. Biochem. 214, 70–76 CrossRef Medline

Tian, E., Kimura, C., Takeda, N., Aizawa, S., and Matsuo, I. (2002) Otx2 is required to respond to signals from anterior neural ridge for forebrain specification. Dev. Biol. 242, 204–223 CrossRef Medline

Soriano, P., Friedman, G., and Lawinger, P. (1991) Promoter interactions in retrovirus vectors introduced into fibroblasts and embryonic stem cells. J. Virol. 65, 14–19

Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K. H., Mistl, C., Rothacher, S., Ledermann, B., Bürgi, K., Frey, P., Paganetti, P. A., Waring, C., Calhoun, M. E., Jucker, M., Probst, A., Staufenbiel, M., et al. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U.S.A. 94, 13287–13292 CrossRef Medline

Ishikawa, T., Gotoh, N., Murayama, C., Abe, T., Iwashita, M., Matsuzaki, F., Suzuki, T., and Yamamoto, T. (2011) IgSF molecule MDGA1 is involved in radial migration and positioning of a subset of cortical upper-layer neurons. Dev. Dyn. 240, 96–107 CrossRef Medline

Iijima, K., Ando, K., Takeda, S., Satoh, Y., Seki, T., Itohara, S., Greengard, P., Kirino, Y., Nairn, A. C., and Suzuki, T. (2000) Neuron-specific phosphorylation of Alzheimer's β-amyloid precursor protein by cyclin-dependent kinase 5. J. Neurochem. 75, 1085–1091 CrossRef Medline

Nakaya, T., and Suzuki, T. (2006) Role of APP phosphorylation in FE65-dependent gene transcription mediated by AICD. Genes Cells 11, 633–645 CrossRef Medline

Oishi, M., Nairn, A. C., Czernik, A. J., Lim, G. S., Isohara, T., Gandy, S. E., Greengard, P., and Suzuki, T. (1997) The cytoplasmic domain of Alzheimer's amyloid precursor protein is phosphorylated at Thr654, Ser655, and Thr668 in adult rat brain and cultured cells. Mol. Med. 3, 111–123 CrossRef Medline

Pasquali, C., Fialka, L., and Huber, L. A. (1999) Subcellular fractionation, electromigration analysis and mapping of organelles. J. Chromatogr. B Biomed. Sci. Appl. 722, 89–102 CrossRef Medline